They show up in clinical trial design, in tolerability profiles, in the types of metabolic benefits each compound delivers, and in the practical timelines for when researchers might actually be able to access them
This is generally considered the rate-limiting stage of glutathione synthesis
This compound, as many of you know, is gaining significant traction for its role in inhibiting NNMT (Nicotinamide N-methyltransferase), an enzyme that regulates energy expenditure
Where we go from here Whatever happens, the EVOKE trials are going to change how we think about metabolism and inflammation in neurodegenerative conditions
Chronic inflammation: Speeds up telomere shortening (a key marker of cellular aging)
Pharmacy systems also catch identity errors at the dispensing level